Visual Impairment in Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Creator
Timothy McCulley, Jinglan Pei, Paris Sidiropoulos, Christine Birchwood, Jennie Best, John Stone, Sebastian Unizony
Subject
Vascular Disorders
Description
The GiACTA trial demonstrated the efficacy of tocilizumab (TCZ) in giant cell arteritis (GCA) [1]. However, the effectiveness of TCZ for prevention of specific GCA-related visual manifestations is currently unknown. The incidence of GCA-related visual manifestations was analyzed in patients treated with TCZ in a real-world setting.
Date
2019-03
Language
eng
Format
video/mp4
Source
2019 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS 2019: Scientific Platform III
Collection
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Publisher
Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution
North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
